AADI 3.39 (+46.12%)
US00032Q1040BiotechnologyBiotechnology

Aadi Bioscience (AADI) Stock Highlights

3.39 | +46.12%
2024-12-21 07:13:36
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadis primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.

Statistics

Range Today
2.07 3.6
Volume Today 9.17M
Range 1 Year
1.21 2.63
Volume 1 Year 67.33M
Range 3 Year
1.21 26.2
Volume 3 Year 139.07M
Range 10 Year
0.42 32.99
Volume 10 Year 1.48B

Highlights

Market Capitalization 52.38M (small)
Floating Shares 14.26M
Current Price 3.39
Price To Earnings -0.93
Price To Revenue -1.2
Price To Book 0.5
Earnings Per Share -2.28
Payout Ratio 0%

Performance

Latest +46.12%
1 Month +54.09%
3 Months +85.25%
6 Months +114.56%
1 Year +56.94%
3 Years -86.5%
5 Years +470.71%
10 Years -27.1%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.